Xarostat-F Tablet is a combination lipid-lowering agent containing Fenofibrate 160 mg and Rosuvastatin 20 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent statin, inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby effectively lowering low-density lipoprotein cholesterol (LDL-C) and total cholesterol. The combination therapy offers a complementary mechanism of action, providing comprehensive lipid control in patients inadequately managed by monotherapy. Xarostat-F is indicated for adult patients with mixed dyslipidemia, hypertriglyceridemia, or those at high cardiovascular risk requiring aggressive lipid modification. It should be administered under medical supervision with regular monitoring of lipid profile, liver function tests, and renal parameters to mitigate potential adverse effects such as hepatotoxicity, myopathy, or rhabdomyolysis. Contraindications include active liver disease, severe renal impairment, and hypersensitivity to either component. Dose adjustments may be necessary based on clinical response and tolerability. Patient adherence to lifestyle modifications alongside pharmacotherapy is essential for optimal therapeutic outcomes.